New research out of Texas could go a long way toward improving care for patients with acute decompensated heart failure.

The FDA’s final decision was based largely on positive results from the ADVENT clinical trial, which compared treatment with the Farapulse PFA System to the current standard of care.

Annual SAVR volumes in the United States decreased by a whopping 44.5% from 2012 to 2022. However, heart teams across the country seem to agree that surgery is a safer, more effective treatment option than TAVR when patients present with bicuspid aortic valves. 

Injuries to the esophagus remain a common complication associated with radiofrequency ablation procedures. New research suggests a device developed by S4 Medical could significantly reduce the risk of such injuries. 

The two neighboring practices have joined forces to provide improved cardiovascular care for patients throughout the Sunshine State. 

Nearly 50% of patients under the age of 60 are now opting for TAVR over SAVR, according to a new study presented at STS 2024 in San Antonio. "We owe it to our patients to take a more prominent role in providing the highest quality evidence to help our patients make these major healthcare decisions," one researcher said. 

The device, which also received Great Britain’s UKCA marking, was specifically designed to be less bulky and easier to wear than other wearable cardioverter-defibrillators.

NYU Grossman School of Medicine researchers used artificial intelligence and wearable activity trackers to improve the monitoring and classification of older adult cardiac rehabilitation patients.